| Chapter 7. Molecular imaging of tumor vasculature. | |
| | |
MedLine Citation:
|
PMID: 19022059 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cancer, with more than 10 million new cases a year worldwide, is the third leading cause of death in developed countries. One critical requirement during cancer progression is angiogenesis, the formation of new blood vessels. Structural and functional imaging of tumor vasculature has been studied using various imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound. Molecular imaging, a key component of the 21st-century cancer-patient management strategy, takes advantage of these traditional imaging techniques and introduces molecular probes to determine the expression of indicative molecular markers at different stages of cancer development. In this chapter, we will focus on two tumor vasculature-related targets: integrin alpha(v)beta(3) and vascular endothelial growth factor receptor (VEGFR). For imaging of integrin alpha(v)beta(3) on the tumor vasculature, only nanoparticle-based probes will be discussed. VEGFR imaging will be discussed in depth, and we will give a detailed example of positron emission tomography (PET) imaging of VEGFR expression using radio-labeled VEGF(121) protein. Future clinical translation will be critical for maximum patient benefit from these agents. To achieve this goal, multidisciplinary approaches and cooperative efforts from many individuals, institutions, industries, and organizations are needed to quickly translate multimodality tumor vasculature imaging into multiple facets of cancer patient management. |
| | |
Authors:
|
Weibo Cai; Sanjiv S Gambhir; Xiaoyuan Chen |
Related Documents
:
|
15789319 - Positron emission tomography/computed tomography true fusion imaging in clinical head a... 19638859 - Magnetic resonance imaging of endometrial carcinoma. 10823629 - Value of (18f)-fdg positron emission tomography, computed tomography, and magnetic reso... 20146589 - Role of pet/ct imaging in stereotactic body radiotherapy. 7769939 - Preoperative identification of benign versus malignant parotid masses: a comparative st... 19692289 - Advances in imaging in the work-up of head and neck cancer patients. 16165239 - Comparison of simulator-ct versus simulator fluoroscopy versus surface marking based ra... 17102039 - Normal and pathologic features of the postoperative biliary tract at 3d mr cholangiopan... 20487149 - Magnetic fingerprint powder from a mineral indigenous to thailand. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Methods in enzymology Volume: 445 ISSN: 1557-7988 ISO Abbreviation: Meth. Enzymol. Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-11-21 Completed Date: 2009-04-10 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 0212271 Medline TA: Methods Enzymol Country: United States |
Other Details:
|
Languages: eng Pagination: 141-76 Citation Subset: IM |
Affiliation:
|
Stanford University School of Medicine, Stanford, California, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Humans Integrin alphaVbeta3 / metabolism Magnetic Resonance Imaging Neoplasms / blood supply*, pathology*, radiography, radionuclide imaging Neovascularization, Pathologic / pathology*, radiography, radionuclide imaging Positron-Emission Tomography Receptors, Vascular Endothelial Growth Factor / metabolism Tomography, X-Ray Computed |
| Grant Support | |
ID/Acronym/Agency:
|
P50 CA114747/CA/NCI NIH HHS; R01 CA082214/CA/NCI NIH HHS; R01 CA119053/CA/NCI NIH HHS; R01 HL078632/HL/NHLBI NIH HHS; R21 CA102123/CA/NCI NIH HHS; R21 CA121842/CA/NCI NIH HHS; R24 CA93862/CA/NCI NIH HHS; U54 CA119367/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Integrin alphaVbeta3; EC 2.7.10.1/Receptors, Vascular Endothelial Growth Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Next Document: Chapter 8. Proteomic mapping of the vascular endothelium in vivo for vascular targeting.